Artivion, Inc.
AORTHealthcareNASDAQMedical Devices · Last scanned May 29, 2026
Scan Results
Daily timeframePart of the healthcare sector, Artivion, Inc. (AORT) is listed under Medical Devices. At a $1.10B market cap, Artivion, Inc. ranks as a small-cap company within healthcare. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system.
Market Cap
$1.10B
Beta
1.40
P/E (TTM)
90.28
P/E (Fwd)
29.19
EPS (TTM)
$0.25
EPS (Fwd)
$0.77
ROE
3.1%
ROA
2.8%
Cash
$55.8M
Total Debt
$258.2M
Free CF
-$7.3M
52W Change
-23.7%
Annual Financials
Cash vs Debt
The company holds $55.8M in cash, though total debt stands at $258.2M. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$7.3M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at 3.1%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $313.8M (2022) to $441.3M (2025), reflecting a 41% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. The elevated P/E ratio means the stock is priced for significant future growth. If earnings disappoint, the price correction could be sharp. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Artivion, Inc. and its sector.